Trials / Active Not Recruiting
Active Not RecruitingNCT06512337
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 153 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | As per product label |
Timeline
- Start date
- 2025-01-20
- Primary completion
- 2027-03-11
- Completion
- 2027-03-11
- First posted
- 2024-07-22
- Last updated
- 2026-04-15
Locations
5 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06512337. Inclusion in this directory is not an endorsement.